quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:35:00·37d
PRRelease
Immuneering Corporation logo

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

IMRX· Immuneering Corporation
Health Care
Original source

Companies

  • IMRX
    Immuneering Corporation
    Health Care

Recent analyst ratings

  • Oct 31UpdateLeerink Partners$15.00
  • Dec 13UpdateMorgan Stanley-
  • Mar 15UpdateNeedham$15.00
  • Mar 15UpdateTD Cowen-
  • Mar 15UpdateJefferies$3.00
  • Dec 1UpdateNeedham$20.00

Related

  • PR2d
    Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
  • SEC3d
    SEC Form DEFA14A filed by Immuneering Corporation
  • SEC3d
    SEC Form DEF 14A filed by Immuneering Corporation
  • PR3d
    Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
  • PR17d
    Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
  • INSIDER37d
    CHIEF PEOPLE OFFICER Neufeld Leah R was granted 3,628 shares, increasing direct ownership by 14% to 29,598 units (SEC Form 4)
  • SEC48d
    SEC Form 10-K filed by Immuneering Corporation
  • SEC48d
    Immuneering Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022